Clinical trial
A Double-Blinded, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Uncontrolled Type 2 DM Subjects on Diet Control Alone, Metformin Monotherapy, or Two or Three Oral Glucose-lowering Agents
NCT04817215 is registered in ClinicalTrials.gov with King Hamad University Hospital, Bahrain as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blinded, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Uncontrolled Type 2 DM Subjects on Diet Control Alone, Metformin Monotherapy, or Two or Three Oral Glucose-lowering Agents
- Lead sponsor
- King Hamad University Hospital, Bahrain
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- October 31, 2021
- Completion date
- July 31, 2022
- Enrollment
- 608 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.